Oral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer

This study is testing a combination of oral vinorelbine (a chemotherapy pill taken in low, frequent doses, called "metronomic" dosing) together with a PD-1 inhibitor (a type of immunotherapy) for older patients with non-small cell lung cancer (NSCLC) who have no specific gene mutations. This approach may be gentler than standard chemotherapy while still being effective in elderly patients. **You may be eligible if...** - You are 65 years of age or older - You have been confirmed to have non-small cell lung cancer without specific driver gene mutations (such as EGFR or ALK) - You have not yet received any first-line treatment for lung cancer - You are in reasonably good physical condition (KPS ≥70 or ECOG 0–1) - Your expected survival is at least 3 months - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have already received first-line treatment for this cancer - You have serious organ dysfunction - You have active infections or uncontrolled medical conditions - You have certain driver gene mutations that would call for different targeted therapies Talk to your doctor to see if this trial is right for you.